Oral Dosage Forms

乐发lll-追求健康,你我一起成长

Technology Platform

APIs Technology Platform
Drug Product Platform Technology

Physicochemical and Biopharmaceutical Characterization of Medicinal Compounds/Drug Substances Salt and Polymorph Screening Preclinical Animal Formulation Development and Their In Vitro and In Vivo Evaluation Poorly Soluble Drug Solubilization Technology Platform Liquid Dosage Form Platform Topical Dosage Forms Oral Dosage Forms Pediatric Dosage Forms

For more information about

“Oral Dosage Forms”

please contact our team.

Contact Us

Oral Dosage Forms

Oral medications, including tablets, capsules, granules, and liquid formulations, play a vital role in modern medicine by providing effective treatment options for a wide range of diseases. Langhua Pharmaceutical has a well-established platform for the research, development, and production of oral dosage forms, offering the following services.

Scope of Services

Oral solution, suspension，and emulsion dosage form development
Oral tablet dosage form development:Immediate released/control released/delay released tablets and mini-tablets, oral disintegrating tablet, chewable tablet, effervescent tablet, bilayer tablet.
Oral capsule dosage form development: Immediate released/control released/delay released hard gelatin or HPMC capsules.
Oral particulate dosage form development: Immediate released/Control released/Delay released multiple particulates
Oral Control released/Delay released ion exchange resin dosage form development.

The Key Advantages of the Platform

The primary advantage of our platform is its ability to provide a one-stop solution for oral dosage form development, particularly for oral solid dosage forms, from clinical stages to commercial launch. Langhua Pharmaceutical has established a cGMP-compliant formulation production facility at its Shanghai R&D center, spanning nearly 1,000 square meters. This facility features strictly segregated functional areas equipped for the preparation of oral solid dosage forms, oral liquid dosage forms, and other non-sterile oral formulations, thereby meeting clients' clinical Phase I and II formulation needs. Additionally, Langhua has established strategic collaborations with external pharmaceutical companies to fulfill clients' clinical Phase III and commercial formulation requirements.